UCB (UCBJF) Other Gross PPE : $1,049 Mil (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is UCB Other Gross PPE?

UCB's Other Gross PPE for the quarter that ended in Dec. 2024 was $1,049 Mil.

UCB's quarterly Other Gross PPE increased from Dec. 2023 ($1,039 Mil) to Jun. 2024 ($1,792 Mil) but then declined from Jun. 2024 ($1,792 Mil) to Dec. 2024 ($1,049 Mil).

UCB's annual Other Gross PPE increased from Dec. 2022 ($957 Mil) to Dec. 2023 ($1,039 Mil) and increased from Dec. 2023 ($1,039 Mil) to Dec. 2024 ($1,049 Mil).

UCB Other Gross PPE Historical Data

The historical data trend for UCB's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Other Gross PPE Chart

UCB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Gross PPE

Get a 7-Day Free Trial

896.59

935.59

956.57

1,039.26

1,049.21

UCB Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Gross PPE	Get a 7-Day Free Trial															956.57	1,645.72	1,039.26	1,792.25	1,049.21

UCB Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

UCB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (OTCPK:UCBJF) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

UCBJY:USA UCBb:UK 0NZT:UK UNC:Germany UCB:Belgium UCB:Austria

Address

Allee de la Recherche, 60, Brussels, BEL, B-1070

Website

https://www.ucb.com

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).